Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Unjha Formulations Ltd (531762)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 531762 NSE: Pharmaceuticals & Drugs | Small Cap | Unjha Formulations Share Price
₹32.02 1.52 (4.98%)
As on 25-Sep'26 16:59
Unjha Formulations Ltd (531762)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 531762 NSE: Pharmaceuticals & Drugs | Small Cap | Unjha Formulations Share Price
₹32.02 1.52 (4.98%)
As on 25-Sep'26 16:59
Key Metrics
Valuation Multiples
Market Cap
₹14 Cr.
Current Price
₹32
52-Week Low / High
₹18 / 36
TTM EPS
-
TTM Sales
-
Book Value per Share
-
P/E Ratio
Industry PE
54.9
Price to Book (P/B)
Price to Sales (P/S)
EV/EBITDA
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
%
Return on Capital Employed (ROCE)
%
Return on Assets (ROA)
%
Operating Profit Margin
0%
Net Profit Margin
-%
Gross Profit Margin
0%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
12.48%
Operating Profit Growth (1 Year)
-
-
Net Profit Growth (1 Year)
-
-
Asset Quality
Promoter Holding
36.92%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
-
Equity
₹4.5 Cr.
Face Value
₹10
All Time Low / High
₹1.00 / 39.00
Check Before You Invest
M-Cap below 100cr DeciZen not available
Is Unjha Formulations Ltd a good quality company?
Unjha Formulations Ltd is a quality company, based on a multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Unjha Formulations Ltd performance compare with that of its Peers?
Revenue growth of Unjha Formulations Ltd vs industry peers?
Unjha Formulations Ltd revenue CAGR is %, compared to the industry median CAGR of 0%, indicating stable growth and maintaining its market share.
Promoter shareholding and pledge status of Unjha Formulations Ltd?
Promoters hold 36.92% of the Unjha Formulations Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of Unjha Formulations Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 10.8% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Unjha Formulations Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good
Value Creation ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 67.6% | 32.2% | 25.4% | 25.6% | 26.8% | 21.1% | 16.8% | 19.5% | 18.1% | 27.5% | - |
| Value Creation Index ⓘ | 3.8 | 1.3 | 0.8 | 0.8 | 0.9 | 0.5 | 0.2 | 0.4 | 0.3 | 1.0 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 12.2 | 11.3 | 11.4 | 10.6 | 10 | 14.2 | 13.2 | 18.5 | 13.9 | 15.6 | 15 |
| Sales YoY Gr. | - | -7.7% | 1.1% | -7.2% | -6% | 42.2% | -7.1% | 40.7% | -25.1% | 12.5% | - |
| Adj EPS ⓘ | 0.7 | 0.6 | 0.7 | 0.7 | -0 | 0.3 | 0.6 | 0.6 | 0.9 | 1.4 | 1.1 |
| YoY Gr. | - | -10.6% | 13.6% | 1.5% | -104.4% | NA | 87.5% | 3.3% | 50% | 50.5% | - |
| BVPS (₹) ⓘ | 1.6 | 2.2 | 3.4 | 4.1 | 4.3 | 4.9 | 5.5 | 6.1 | 7 | 8.6 | 8.9 |
| Adj Net Profit ⓘ | 0.3 | 0.3 | 0.3 | 0.3 | -0 | 0.1 | 0.3 | 0.3 | 0.4 | 0.6 | 0 |
| Cash Flow from Ops. ⓘ | 0.4 | 0.1 | -0.1 | 0.4 | -0.7 | 0.3 | -0.3 | 1 | -0 | 1.2 | - |
| Debt/CF from Ops. ⓘ | 0.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 2.7% | 9.4% | 5.8% | 12.5% | ||||
| Adj EPS ⓘ | 8.7% | NA | 32.6% | 50.5% | ||||
| BVPSⓘ | 20.6% | 14.9% | 16.1% | 22.4% | ||||
| Share Price | 11.3% | 26.9% | 17% | 28.1% | ||||
Key Financial Parameters ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 37.1 | 24.4 | 22 | 18.4 | -0.8 | 7 | 11.6 | 10.7 | 14.2 | 18 | 12 |
| Op. Profit Mgn % ⓘ | 3.1 | 3 | 2.6 | 2.3 | 3.7 | 2.3 | 3.3 | 3.1 | 3.7 | 6 | 5.7 |
| Net Profit Mgn % ⓘ | 2.4 | 2.3 | 2.6 | 2.9 | -0.2 | 1 | 2 | 1.5 | 3 | 4 | 3.1 |
| Debt to Equity ⓘ | 0.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| Working Cap Days ⓘ | 51 | 65 | 63 | 61 | 71 | 54 | 59 | 52 | 74 | 62 | 56 |
| Cash Conv. Cycle ⓘ | -29 | -36 | -26 | -13 | 2 | 13 | 23 | 19 | 26 | 21 | 34 |
Valuation of Unjha Formulations - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
No data found!
No data found!
No data found!
No data found!
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Unjha Formulations Ltd FAQs
The current trading price of Unjha Formulations on 25-Sep-2026 16:59 is ₹32.02.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 24-Sep-2026 the market cap of Unjha Formulations stood at ₹14.35 Cr
The latest P/E ratio of Unjha Formulations as of 24-Sep-2026 is 30.52.
The latest P/B ratio of Unjha Formulations as of 24-Sep-2026 is 3.59.
The 52-week high of Unjha Formulations is ₹36.38 and the 52-week low is ₹17.52.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Unjha Formulations is ₹15.28 ( Cr.) .
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Unjha Formulations Ltd is a below average quality company.
The key valuation ratios of Unjha Formulations Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Unjha Formulations Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
About Unjha Formulations Ltd
Unjha Formulations (U-For), incorporated in 1987, is the sister concern of Urvesh Psyllium Industries Limited. U-For is the pharmaceuticals manufacturing unit, which is going to various category of formulation like tablet, capsule, oral liquids, injectables (SVP) and powder section to manufacture ayurvedic as well as allopathy products.
Fibron Powder & Fibron Sugar Free Powder are the branded ayurvedic products of the company, based on psyllium husk. The products met with an overwhelming success in our domestic market. The products mainly caters to somewhat sophisticated market segment who is conscious about their health and at the same time are very particular about various flavour like Orange, Lemon, Lime & Mango taste of the product.
Fibron Powder & Fibron SF powder offer excellent value for the money. Speed U - for could able to promote Fibron Powder & Fibron Powder SF at a most competitive price without sacrificing on quality mainly because their sister concern unit Urvesh Psyllium Industries Ltd. is one of the largest raw material supplier and processor of plyllium in the world. It may be important to note here that even Glaxo India Ltd, Proctor & Gamble, Nicholas Piramal India Ltd are the company's most valued costumers.
The company has entered into an agreement with Nicholas Piramal India for sale of Isabgol Husk based product `Tybogel` and Morepen Laboratories for sale of Dr.Mopren Sat Isabgol.
Urvesh Psyllium Industries Limited is the leading processor and exporter of Psyllium Husk & Powder in India.The company is in this line of business since last 52 years (i.e. from 1949). Initially it processed and supplied Psyllium products in local market but, looking to the worldwide demand, in 1966 it started to export Psyllium Products in the name of Rajendra Brothers. Later on with the increase of demand from overseas buyers there rose a need to expand the business, and thus Urvesh Psyllium Industries was formed in 1985, which later on was converted into a Limited Company in the year 1995.
Product range of the company includes:
- Fibron Powder
- Fibron Sugar Free Powder
- Psyllium Capsules
Achievements/ recognition:
- GMP & ISO:9001-2000 certified unit.
You have 42 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
